Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 9, 2025
Orion julkaisee osavuosikatsauksen 1–3/2025 ja järjestää verkkolähetyksen 23.4.2025
GlobeNewswire
·
April 9, 2025
ORION OYJ LEHDISTÖTIEDOTE 9.4.2025 KLO 13.30 Orion julkaisee osavuosikatsauksen 1–3/2025 ja järjestää verkkolähetyksen 23.4.2025 Orion julkaisee osavuosikatsauksen 1–3/2025 keskiviikkona 23.4.2025 noin klo 12.00. Tiedote ja siihen …
Coave Therapeutics to Attend Upcoming Conferences
GlobeNewswire
·
April 9, 2025
Paris, France, April 9, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, announces that members of its leadership team will be attending the following industry conferences: Cell …
برنامج "مسيرة المرأة الإماراتية" يرحب ب 62 منتسبة جديدة للمشاركة في الدفعة الثانية
GlobeNewswire
·
April 9, 2025
أبوظبي، الإمارات العربية , April 09, 2025 (GLOBE NEWSWIRE) -- تحت رعاية سموّ الشيخة فاطمة بنت مبارك، رئيسة الاتحاد النسائي العام، رئيسة المجلس الأعلى للأمومة والطفولة، الرئيسة الأعلى لمؤسَّسة التنمية الأسرية "أم الإمارات"، وبالتعاون مع الاتحاد النسائي …
Emirati Women Chapter Onboards Second Cohort of 62 Participants
GlobeNewswire
·
April 9, 2025
ABU DHABI, United Arab Emirates, April 09, 2025 (GLOBE NEWSWIRE) -- Under the patronage of Her Highness Sheikha Fatima bint Mubarak, Chairwoman of the General Women's Union (GWU), President of the Supreme Council for Motherhood and Childhood (SCMC), …
Barbara Weber, M.D., Elected to ITM Supervisory Board
GlobeNewswire
·
April 9, 2025
Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election …
ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer
GlobeNewswire
·
April 9, 2025
Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infections Study to be led by global health physician scientist, Dr. Justin Ortiz, Professor of Medicine at the University of Maryland …
Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development
GlobeNewswire
·
April 9, 2025
First-ever use of Ebenbuild’s Twinhale technology in idiopathic pulmonary fibrosis lung models Trial results published in Nature Communications Munich, Germany – April 9, 2025 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of …
SBC Medical to Present at the Emerging Growth Conference on April 17, 2025
GlobeNewswire
·
April 9, 2025
IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global franchise and provider of services for aesthetic clinics, is pleased to announce that it has been invited to …
Cytosurge Appoints Magid Haddouchi as Chief Commercial Officer
GlobeNewswire
·
April 9, 2025
ZURICH, Switzerland, April 09, 2025 (GLOBE NEWSWIRE) -- Cytosurge AG, a leading biotech company in single-cell manipulation and cell engineering solutions, announces the appointment of Magid Haddouchi, PhD, as its new Chief Commercial Officer (CCO), …
ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO
GlobeNewswire
·
April 9, 2025
HELSINKI and NAPLES, Italy, April 09, 2025 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella Origgi as its Chief Executive Officer (CEO …
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
GlobeNewswire
·
April 9, 2025
– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations – – Additional poster presentation highlights new insights in genital …
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
GlobeNewswire
·
April 9, 2025
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025 New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab NANTES, France – …
OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025
GlobeNewswire
·
April 9, 2025
OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025 Présentation de nouvelles données cliniques sur les bénéfices et la sécurité à long terme de l’anticorps monoclonal …
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
GlobeNewswire
·
April 9, 2025
Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life- …
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2
GlobeNewswire
·
April 9, 2025
Saint Herblain (France) et Schlieren (Zurich), le 9 avril 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, et LimmaTech Biologics AG, société de biotechnologies développant des vaccins pour la prévention de …
Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors
GlobeNewswire
·
April 9, 2025
New Chair brings more than three decades of life sciences industry experience, with a successful track record as a biotech company board member Significant leadership experience will be instrumental as Augustine transitions into a clinical-stage company …
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension
GlobeNewswire
·
April 9, 2025
Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertension Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX …
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement
GlobeNewswire
·
April 9, 2025
Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX: IDIA) today announced that the US Food …